Last checked at 4 Nov 2014 07:00
PRESS RELEASE
4 November 2014
SYNAIRGEN PLC
("Synairgen" or "the Company")
Grant of options
Southampton, UK, 4 November 2014: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 3 November 2014 the Board of Synairgen granted options ("Options") over 1,086,997 ordinary shares of one pence each in the capital of the Company ("Ordinary Shares") at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 1.19 per cent of the existing issued share capital.
The Options are issued under the Company's existing Long Term Incentive Plan and are exercisable between 3 November 2017 and 2 November 2024, subject to achievement of performance criteria related to the increase in the total shareholder return of the Company.
The following Options were issued to directors of the Company on 3 November 2014:
Director | Options Issued |
Richard Marsden | 313,827 |
Dr. Phillip Monk | 233,425 |
John Ward | 285,297 |
Following the issue of the Options, the interests of the directors of the Company at 3 November 2014 are as follows:
Director | Total options issued | Ordinary shares | Total interest | Percentage holding of fully diluted share capital |
Richard Marsden | 1,949,511 | 110,972 | 2,060,483 | 2.13% |
Dr. Phillip Monk | 866,413 | 161,710 | 1,028,123 | 1.06% |
John Ward | 1,322,283 | 243,912 | 1,566,195 | 1.62% |
Simon Shaw (Note 1) | - | 1,408,879 | 1,408,879 | 1.46% |
Iain Buchanan | 212,765 | 112,741 | 325,506 | 0.34% |
Dr. David Campbell | - | 294,259 | 294,259 | 0.30% |
Paul Clegg (Note 2) | 250,000 | 204,244 | 454,244 | 0.47% |
Prof. Stephen Holgate (Note 3) | - | 858,360 | 858,360 | 0.89% |
Note 1. Simon Shaw's shareholding includes 40,299 shares held in his pension plan.
Note 2. Paul Clegg's shareholding includes 180,149 shares held in his pension plan.
Note 3. The holding of Professor Stephen Holgate includes 1,923 shares owned by his wife, Elizabeth Holgate.
ENDS
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Christopher Raggett (Corporate Finance)
Stephen Norcross, Simon Johnson (Corporate Broking)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Jessica Hodgson / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5702
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology Biobank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The Biobank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com